General Information

Macrilen (macimorelin)  is a growth hormone (GH) secretagogue receptor agonist.

Macrilen is specifically indicated for the diagnosis of adult growth hormone deficiency.

Macrilen is supplied as a solution for oral administration. The recommended dose is a single oral dose of 0.5 mg/kg of macimorelin.  The dose is administered as a reconstituted solution.

Mechanism of Action

Macrilen (macimorelin)  is a growth hormone (GH) secretagogue receptor agonist. Macimorelin stimulates GH release by activating growth hormone secretagogue receptors present in the pituitary and hypothalamus. 

Side Effects

Adverse effects associated with the use of Macrilen may include, but are not limited to, the following: 

• dysgeusia
• dizziness
• headache
• fatigue
• nausea
• hunger
• diarrhea
• upper respiratory tract infection
• feeling hot
• hyperhidrosis
• nasopharyngitis
• sinus bradycardia

Clinical Trial Results

The FDA approval of Macrilen was based on  a randomized, open-label, single-dose, cross-over study in 154 subjects. The objective of the study was to compare the level of agreement between Macrilen test results and insulin tolerance test (ITT) results in adult patients with different pre-test probability of growth hormone deficiency and healthy control subjects. The four groups of individuals evaluated were: Group A:  Adults with a high likelihood of growth hormone deficiency (GHD); Group B:  Adults with an intermediate likelihood of GHD; Group C:  Adults with a low likelihood of GHD and Group D: healthy adults. Overall, Macrilen and the ITT were in complete agreement among 84% of all subjects. Among those with a high likelihood of AGHD prior to testing, Macrilen and the ITT were in complete agreement among 89% of subjects. Macrilen was evaluable in >99% of tests at first try, compared to 83% evaluable with the ITT. Repeatability was observed in 91.2% of the patients (n=34) who underwent two Macrilen tests.